Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jyong BiotechMENS +4.26%10 Equity-to-Asset is -1.20 as of Dec. 2025. GuruFocus rates MENS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Jyong Biotech ranks worse than 93.91% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Jyong Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-24.91 Mil. Jyong Biotech's Total Assets for the quarter that ended in Dec. 2025 was $20.78 Mil.
The historical rank and industry rank for Jyong Biotech's Equity-to-Asset or its related term are showing as below:
MENS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -5.74 Med: -3.39 Max: -1.2
Current: -1.2
During the past 5 years, the highest Equity to Asset Ratio of Jyong Biotech was -1.20. The lowest was -5.74. And the median was -3.39.
MENS's Equity-to-Asset is ranked worse than 93.91% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs MENS: -1.20
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Jyong Biotech Equity-to-Asset Related Terms
Jyong Biotech Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Jyong Biotech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MENS vs CNTN, SPRB, CDXS: Equity-to-Asset Comparison
For the Biotechnology subindustry, Jyong Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jyong Biotech Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jyong Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Jyong Biotech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Jyong Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jyong Biotech (MENS) has a Equity-to-Asset of -1.20 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Jyong Biotech and its competitors. According to the industry distribution chart, Jyong Biotech ranks #1326 out of 1412 companies in the Biotechnology industry, placing it in the top 93.9%.
Is Jyong Biotech's Equity-to-Asset too high?
Jyong Biotech's current Equity-to-Asset is -1.20. Based on the distribution chart, Jyong Biotech ranks #1326 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jyong Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Jyong Biotech's Equity-to-Asset compare to CNTN and SPRB?
According to the Biotechnology industry distribution chart, Jyong Biotech ranks #1326 out of 1412 companies for Equity-to-Asset. This places Jyong Biotech in the lower half of its industry. The industry median Equity-to-Asset is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Jyong Biotech and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jyong Biotech's current Equity-to-Asset is -1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jyong Biotech stock overvalued right now?
Jyong Biotech (MENS) has a current Equity-to-Asset of -1.20. The current Equity-to-Asset is -1.20. Jyong Biotech's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Jyong Biotech (MENS), the current Equity-to-Asset is -1.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score
Get the complete analysis for MENS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MENS has been successfully added to your 
